This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-30 and is reviewed periodically as new material appears.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
One of those was the idea that when introducing a new mechanic, the level was designed to teach the new mechanic without potential harm to the player-character, followed by then testing that mechanic in a more harmful situation to the character. The team also included a brief mention to the long-fall boots from Aperture Science from the Portal series; Portal had come out after Half-Life 2 but loosely tied narratively to the Half-Life universe, and the team felt it appropriate to show the competing lab's technology within the Black Mesa facility from this connection. Once the team had gotten all but the Xen levels completed in the new Source engine they were content with, they released these on Steam's early access on May 5, 2015, to get feedback and bug testing, stating that the Xen sections were still a work in progress. This version also included the deathmatch multiplayer modes with some of Half-Life's remade maps. Early access also brought Crowbar Collective additional support from developers and artists to help with finalizing the project.
=== Intracrines and regenerative Medicine === The discovery of intracrine loops in stem cell regulation has profound implications for regenerative medicine. Because intracrines can establish long-lasting differentiation programs, they offer potential therapeutic targets for tissue regeneration and repair. For example, in cardiac repair, HMGB1 has been shown to enhance the proliferation and differentiation of cardiac stem cells following myocardial infarction, suggesting that modulating intracrine pathways could improve heart regeneration. The ability of certain intracrines to reprogram cells into pluripotent-like states also opens new avenues for regenerative therapies. Oct3/4, Sox2, and Nanog, all of which are involved in maintaining stem cell pluripotency, can potentially be introduced into cells to drive reprogramming without the need for genetic modification. This approach could provide safer and more controlled methods for generating patient-specific stem cells.
Treatment depends partly on the cause and severity of the disease. There are three main treatment options: radioiodine therapy, medications, and thyroid surgery. Radioiodine therapy involves taking iodine-131 by mouth, which is then concentrated in and destroys the thyroid over weeks to months. The resulting hypothyroidism is treated with synthetic thyroid hormone. Medications such as beta blockers may control the symptoms, and anti-thyroid medications such as methimazole may temporarily help people while other treatments are having an effect. Surgery to remove the thyroid is another option. This may be used in those with very large thyroids or when cancer is a concern. In the United States, hyperthyroidism affects about 1.2% of the population. Worldwide, hyperthyroidism affects 2.5% of adults. It occurs between two and ten times more often in women. Onset is commonly between 20 and 50 years of age. Overall, the disease is more common in those over the age of 60 years. Thyroid disorders affect kidney function markers and may also affect underlying kidney function. Studies suggest that creatinine may decrease in hyperthyroidism and increase in hypothyroidism, whereas cystatin C shows the opposite pattern. Therefore, the effect of thyroid disorders on underlying kidney function remains debated, and it is unclear whether these changes primarily reflect alterations in kidney markers or changes in underlying kidney function.
=== Haematoxylin === Haematoxylin (hematoxylin in North America) is a nuclear stain. Used with a mordant, haematoxylin stains nuclei blue-violet or brown. It is most often used with eosin in the H&E stain (haematoxylin and eosin) staining, one of the most common procedures in histology.
=== Snakes === Snakes that consume a diet largely composed of goldfish and feeder minnows are susceptible to developing thiamine deficiency. This is often a problem observed in captivity when keeping garter and ribbon snakes that are fed a goldfish-exclusive diet, as these fish contain thiaminase, an enzyme that breaks down thiamine.
Sources: en.wikipedia.org
Hooker Hamersley (1865), heir, lawyer, and poet; former president of the Knickerbocker Club Shipley Jones (1868), banker and clubman William Bayard Cutting (1869), financier, philanthropist, namesake of the Bayard Cutting Arboretum State Park Robert Fulton Cutting (1871), financier George Beach de Forest Jr. (1871), capitalist, bibliophile, and art collector Stuyvesant Fish (1871), president of the Illinois Central Railroad James Montaudevert Waterbury Sr. (1873), industrialist, co-founder of the New York Yacht Club Isaac Newton Seligman (1876), heir to investment bank J. & W. Seligman & Co. T. J. Oakley Rhinelander (1878), heir and real estate developer who owned the Schönburg castle in Germany William Fellowes Morgan Sr. (1880), businessman, philanthropist George Henry Warren II (1880), stockbroker and real estate developer who co-founded the Metropolitan Opera and Real Estate Company Eugene Higgins (1882), heir and philanthropist Lewis Morris Rutherfurd Jr. (1882), socialite and sportsman Marshall Orme Wilson (1882), banker and socialite, son-in-law of William Backhouse Astor Jr. George M. La Monte* (1884), chairman of Prudential Financial 1925–1927 Joseph P. Knapp* (1884), businessman, philanthropist, founder of Ducks Unlimited Temple Bowdoin (1885), former executive of J.P. Morgan & Co. Benjamin Guggenheim* (1887), businessman, son of Meyer Guggenheim and member of the Guggenheim family Richard Thornton Wilson Jr.
== Draw station == A phlebotomy draw station is a place where blood is drawn from patients for laboratory testing, transfusions, donations, or research purposes. The blood is typically drawn via venipuncture or a finger stick by a healthcare professional such as a phlebotomist, nurse, or medical assistant. The draw station typically includes a padded chair or a bed for patients prone to fainting during blood draws. Draw stations can be found in various settings, such as hospitals, clinics, blood donation centers, and independent laboratories or as part of patient service centers (PSC).
Termination of the growing polypeptide chain occurs when the ribosome encounters a stop codon (UAA, UAG, or UGA) in the mRNA molecule. When this occurs, no tRNA can recognise it and a release factor induces the release of the complete polypeptide chain from the ribosome.
The most abundant transdermal drug administration route currently is via hypodermic needles, transdermal patches, and topical creams. However, these routes have limited therapeutic effects because stratum corneum serves as a barrier that reduces the entry of drug molecules into the systemic circulation and target tissues. The invention of MNs have retained the benefits of both hypodermic needles and transdermal patches while minimizing their cons. Compared to hypodermic needles, MNs provide a pain-free administration. MNs are able to penetrate through the epidermis, but not any deeper to compress on nerve-ends to produce pain responses. The superficial penetration also lessens the infection risk. Compared to transdermal patches, MNs are proven to be effective in producing micropores on the epidermis. The micropores facilitate the absorption of large molecules, like calcein and insulin, by 4 times via in-vitro skin models. In addition, MNs' direct drug delivery to systemic circulation avoided the first-pass effect in the liver. Significantly increasing the drug bioavailability, and the fast absorption into the systemic circulation also allowed a fast onset of action. Therefore, MNs could benefit diabetes treatment as common oral delivery would lead to a significant loss of insulin from degradation in the liver (first-pass effect) and insulin molecules are too large to be absorbed using common transdermal patches.
== Structure == The dermis is composed of three major types of cells: fibroblasts, macrophages, and mast cells. Apart from these cells, the dermis is also composed of matrix components such as collagen (which provides strength), elastin (which provides elasticity), and extrafibrillar matrix, an extracellular gel-like substance primarily composed of glycosaminoglycans (most notably hyaluronan), proteoglycans, and glycoproteins.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.